close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

166.89 -0.68 (-0.41%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
58 59 Next >
News headline image
Vir Bio (VIR) Q3 2026 Earnings Call Transcript ↗
Gilead deal and 2028 cash runway frame upcoming hepatitis data. 
Via The Motley Fool
Topics Earnings
News headline image
Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe. ↗
Gilead Sciences increased its quarterly dividend by 3.8% this year. 
Via The Motley Fool
News headline image
What Vir Biotechnology (VIR) Said on Its Q3 Earnings Call ↗
Vir Biotechnology (NASDAQ:VIR) expects to report the first phase 3 results for its experimental hepatitis delta treatment in the fourth quarter of 2026, with data from two additional studies due in the... 
Via MarketBeat
Topics Earnings
Gilead Sciences (NASDAQ:GILD): A Dividend Quality Candidate for Income Investors ↗
Via Chartmill
Gilead Sciences (NASDAQ:GILD) Posts Q3 Beat but Shares Stay Flat as Raised Guidance Is Roughly In Line ↗
Via Chartmill
News headline image
3 S&P 500 stocks we think twice about
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec... 
Via StockStory
Topics Stocks
News headline image
2 Nasdaq 100 stocks to own for decades and 1 we brush off
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win... 
Via StockStory
Topics Artificial Intelligence
News headline image
United Therapeutics (UTHR) to report earnings tomorrow: here is what to expect
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be announcing earnings results this Wednesday before market hours. Here’s what investors should ... 
Via StockStory
News headline image
Earnings to watch: Myriad Genetics (MYGN) reports Q3 results tomorrow
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be announcing earnings results this Wednesday afternoon. Here’s what to expect. Myriad Genetics mi... 
Via StockStory
News headline image
Amgen (AMGN) reports Q3: everything you need to know ahead of earnings
Biotech company Amgen (NASDAQ:AMGN) will be reporting results this Tuesday after market hours. Here’s what you need to know. Amgen beat analysts’ revenue exp... 
Via StockStory
News headline image
BioMarin Pharmaceutical (BMRN) Q3 earnings: what to expect
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be announcing earnings results tomorrow after market hours. Here’s what investors should know. Bio... 
Via StockStory
News headline image
1 Dividend-Paying Biotech Stock to Buy Hand Over Fist in November ↗
The company is having a great year. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Vertex Pharmaceuticals earnings: what to look for from VRTX
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market close. Here’s what to expect. Vertex Pharma... 
Via StockStory
Topics Artificial Intelligence
News headline image
GILD Q3 deep dive: HIV franchise drives growth as policy headwinds loom
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 6.8% year on year... 
Via StockStory
S&P 500 Gap Movers for October 30, 2026 ↗
Via Chartmill
Topics Stocks
News headline image
Gilead (GILD) Q3 2026 Earnings Call Transcript ↗
Base business sales surged 16%, marking strongest growth in over a decade. 
Via The Motley Fool
Topics Earnings
S&P 500 Premarket Gainers and Losers on Oct. 30, 2026 ↗
Via Chartmill
Topics Stocks
News headline image
What Gilead Sciences (GILD) Said on Its Q3 Earnings Call ↗
Gilead Sciences (NASDAQ:GILD) reported third-quarter 2026 base business sales growth of 16% year over year, its strongest growth rate in more than a decade, as HIV products, TRODELVY and Livdelzi drove... 
Via MarketBeat
Topics Earnings
After-Hours S&P 500 Movers: Mondelez and FedEx Freight Gain, Intel and Reddit Fall ↗
Via Chartmill
Topics Stocks
News headline image
Gilead Sciences (NASDAQ:GILD) surprises with Q3 2026 sales, full-year outlook slightly exceeds expectations
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q3 2026, with revenue up 6.8% year on year to $8.3 billion... 
Via StockStory
News headline image
How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decade ↗
Gilead Sciences crushed Wall Street's sales expectations on the back of its HIV treatments and cancer drug Trodelvy. 
Via Investor's Business Daily
News headline image
Gilead Sciences earnings: what to look for from GILD
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after the bell. Here’s what you need to know. Gilead Sciences... 
Via StockStory
News headline image
Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? ↗
BBH offers lower costs and concentrated large-cap exposure, while PBE delivers higher dividend income and slightly better five-year returns through a multifactor strategy. 
Via The Motley Fool
Topics ETFs
News headline image
VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? ↗
These two healthcare ETFs offer investors exposure to some of medicine's biggest names, but their different approaches to investing could lead to very different results. 
Via The Motley Fool
Topics ETFs
News headline image
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? ↗
Both of these biotech stocks could be appealing to income investors. 
Via The Motley Fool
News headline image
Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? ↗
Here's how pharmaceutical stocks compare to biotech in terms of risk, rewards, and costs. 
Via The Motley Fool
Topics ETFs
News headline image
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? ↗
Both of these ETFs look the part, but only one is truly the better buy for investors. 
Via The Motley Fool
Topics ETFs
News headline image
Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day ↗
Arcus Biosciences (NYSE:RCUS) presented updated clinical and translational data for casdatifan, its investigational HIF-2 alpha inhibitor, outlining development plans across first-line, second-line and... 
Via MarketBeat
News headline image
1 Unprofitable Stock with Exciting Potential and 2 We Find Risky
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv... 
Via StockStory
News headline image
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow? ↗
The company's recent momentum continues unabated. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.